Monthly Archives: October 2018

How’s My Baby?
October 24, 2018

This blog was written by Samantha Truex, CEO of Quench Bio and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. In early September, I saw my two teenagers off to new destinations where they will live

Leave a comment

A New Translational Tool for Synaptopathies
October 19, 2018

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After decades of challenges in neuroscience research and development, there is new hope that we can design better clinical

Leave a comment

2018’s Biotech IPO Bonanza: View From the After Market
October 17, 2018

2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years. With lots of pundits

Leave a comment

Science2Startup 2019: Bringing Venture & Academia Together
October 15, 2018

After last year’s inaugural success, we’re excited for 2019’s Science2Startup conference in April 2019, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. Working with a steering committee comprised of Atlas,

Leave a comment

Targeting Aging Comes Of Age
October 11, 2018

This blog is written by Tom Hughes, CEO of Navitor Pharma, as part of the From The Trenches feature of LifeSciVC. We finally are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new

Leave a comment

Bring Your A-Game for BD
October 9, 2018

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. As with most professions – especially those that involve longer-term outcomes – the way people get good at BD is

Leave a comment

Fear Of The Flood: Post-IPO Lockup Expiry In Biotech
October 5, 2018

The dreaded “lockup expiry” is something all newly-minted public biotechs begin to worry about shortly after their offerings. The fear seems reasonable: venture investors and other large shareholders, now free to trade, dump large amounts of stock into the market

Leave a comment

Biotech Climate Change
October 1, 2018

This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC When I first moved from the UK to the US, I told my parents that there was more biotech

Leave a comment